Australian Prescriber最新文献_第10页

Noninvasive prenatal testing: an overview. 无创产前检测：综述。

IF 3.4

Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.019

Alice Poulton, Lisa Hui

{"title":"Noninvasive prenatal testing: an overview.","authors":"Alice Poulton, Lisa Hui","doi":"10.18773/austprescr.2025.019","DOIUrl":"https://doi.org/10.18773/austprescr.2025.019","url":null,"abstract":"Australian health authorities recommend offering prenatal screening for fetal chromosome conditions, also known as aneuploidies (e.g. Down syndrome [trisomy 21]), to all pregnant individuals to support informed decision-making. Noninvasive prenatal testing (NIPT) is one of 3 types of prenatal aneuploidy screening tests available in Australia. NIPT requires a maternal blood test after 10 weeks gestation. Although it doesn't require an ultrasound, a 12- or 13-week ultrasound is recommended as it provides an opportunity for early diagnosis of major structural anomalies. NIPT is not subsidised by Medicare. It is important to take a patient-centred approach when discussing screening options. Patients should be encouraged to consider whether knowing the test result will impact their pregnancy decision-making or preparations. There are two main NIPT approaches: genome-wide and targeted. All currently available NIPT platforms perform well for detecting the common autosomal aneuploidies (trisomy 21, 18 and 13). NIPT has the highest true-positive rate (highest sensitivity) and lowest false-positive rate (highest specificity) among aneuploidy screening methods, however false-positive results can occur. Genetic counselling and confirmatory invasive diagnostic testing are recommended for patients with a high-probability NIPT result, especially if they are considering pregnancy termination.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"47-53"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osilodrostat for Cushing syndrome. 奥西洛司他治疗库欣综合征。

IF 3.4

Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.010

引用次数: 0

The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion. 三联抗栓治疗在房颤和冠状动脉支架置入患者中的作用。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.009

Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop

{"title":"The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion.","authors":"Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop","doi":"10.18773/austprescr.2025.009","DOIUrl":"10.18773/austprescr.2025.009","url":null,"abstract":"Triple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require both dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection. Recent guidelines advocate up to 1 week of triple therapy for most patients, extending up to 1 month for those at high ischaemic risk. In practice, the approach to antithrombotic therapy is individualised by the patient's cardiologist, balancing bleeding and ischaemic risks. General practitioners and pharmacists have an important role in supporting patients in their step-down plan to dual therapy with the oral anticoagulant drug and one of the antiplatelet drugs, and then ongoing monotherapy with the oral anticoagulant drug.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"18-22"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy. 马伐卡坦治疗症状性阻塞性肥厚性心肌病。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.006

引用次数: 0

Propranolol overdose following prescription for anxiety. 服用过量心得安治疗焦虑。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.005

Evan Browne, Jacqueline Huber, Bridin Murnion

引用次数: 0

Australian Prescriber: celebrating 50 years of growth and change. 澳大利亚处方：庆祝50年的成长和变化。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.007

Rosie Scott

引用次数: 0

New drug comments: aiming to deliver useful, timely, independent information for health professionals. 新药评论：旨在为卫生专业人员提供有用、及时、独立的信息。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.002

Tilenka Thynne, Rohan Elliott

引用次数: 0

Teclistamab for relapsed or refractory multiple myeloma. 替司他抗复发或难治性多发性骨髓瘤。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.001

引用次数: 0

Etrasimod for moderate to severe ulcerative colitis. 伊特拉西莫德用于中重度溃疡性结肠炎。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.004

引用次数: 0

Device-assisted therapies for Parkinson disease. 帕金森病的器械辅助疗法。

IF 4.2

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.003

Nadia Mouchaileh, Jillian Cameron

{"title":"Device-assisted therapies for Parkinson disease.","authors":"Nadia Mouchaileh, Jillian Cameron","doi":"10.18773/austprescr.2025.003","DOIUrl":"10.18773/austprescr.2025.003","url":null,"abstract":"Device-assisted therapies for Parkinson disease include apomorphine continuous subcutaneous infusion, levodopa continuous intestinal gel infusion, levodopa continuous subcutaneous infusion and deep brain stimulation. These therapies have a role in managing motor fluctuations and dyskinesias in people with advanced Parkinson disease when symptoms are inadequately controlled with oral and transdermal treatments. Subcutaneous infusion of apomorphine or levodopa are the least invasive device-assisted therapies. Levodopa intestinal infusion is delivered via a surgically placed intestinal tube. Deep brain stimulation involves implanting electrodes into specific target regions of the basal ganglia to modulate brain activity. Selecting an appropriate device-assisted therapy depends on individual factors such as age, comorbidities, symptom severity and patient preferences. Initiation and management require neurologist and multidisciplinary involvement, typically in a specialist movement disorder centre. Primary care clinicians play a crucial role in ongoing support and management for people using these therapies, including monitoring and managing adverse effects and communicating with movement disorder services.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"10-17"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0